Ideally, a validation method would oder fast and reliable assessments of precision on the screening set before employing DEL-ML models for large-scale virtual screening. This would also make it easier to compare models fairly and identify which architectures and methods excel on DEL data. Currently, little to no work exists on developing validation approaches for this issue, largely due to the limited datasets and in vitro results available. We hope that the influx of DEL-ML data from our open science framework, combined with the accumulation of screening data for the same targets using conventional chemical libraries and the same binding assays, will facilitate progress in this area.